A Single-Arm, Open-Label, Multicenter Study of Enfortumab Vedotin (ASG - 22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Recieved Immune Checkpoint Inhibitor (CPI) Therapy
Disease Types
Urothelial Cancer
Available at
Bethesda, Brandywine, Clinton, Columbia, Rockville, Silver Spring, Wheaton
Contact
Linda Iovanni
MOHRSCH@usoncology.com